4w4n - Revision history

OCA at 15:21, 8 November 2023

2023-11-08T15:21:35Z

←Older revision		Revision as of 15:21, 8 November 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4w4n]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4W4N OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4W4N FirstGlance]. <br>		<table><tr><td colspan='2'>[[4w4n]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4W4N OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4W4N FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.8Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [https://pdbe.org/4w4n PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [https://www.ebi.ac.uk/pdbsum/4w4n PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4w4n ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [https://pdbe.org/4w4n PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [https://www.ebi.ac.uk/pdbsum/4w4n PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4w4n ProSAT]</span></td></tr>
	</table>		</table>

OCA at 08:16, 29 March 2023

2023-03-29T08:16:43Z

←Older revision		Revision as of 08:16, 29 March 2023
Line 3:		Line 3:
	<StructureSection load='4w4n' size='340' side='right'caption='[[4w4n]], [[Resolution\|resolution]] 1.80Å' scene=''>		<StructureSection load='4w4n' size='340' side='right'caption='[[4w4n]], [[Resolution\|resolution]] 1.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4w4n]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4W4N OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4W4N FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4w4n]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4W4N OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4W4N FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4w4o\|4w4o]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [https://pdbe.org/4w4n PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [https://www.ebi.ac.uk/pdbsum/4w4n PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4w4n ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IGHG1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [~~http~~://pdbe.org/4w4n PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4w4n PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4w4n ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[~~http~~://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.	+	[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[https://omim.org/entry/254500 254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 24:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Caaveiro~~, J M.M~~]]	+	[[Category: Caaveiro JMM]]
-	[[Category: Kiyoshi, M]]	+	[[Category: Kiyoshi M]]
-	[[Category: Tsumoto, K]]	+	[[Category: Tsumoto K]]
-	~~[[Category: Human fc asymmetry dynamics immune molecule]]~~	+
-	~~[[Category: Immune system~~]]	+

OCA at 08:12, 23 May 2019

2019-05-23T08:12:34Z

←Older revision		Revision as of 08:12, 23 May 2019
Line 1:		Line 1:

	==Crystal structure of human Fc at 1.80 A==		==Crystal structure of human Fc at 1.80 A==
-	<StructureSection load='4w4n' size='340' side='right' caption='[[4w4n]], [[Resolution\|resolution]] 1.80Å' scene=''>	+	<StructureSection load='4w4n' size='340' side='right'caption='[[4w4n]], [[Resolution\|resolution]] 1.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4w4n]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4W4N OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4W4N FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4w4n]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4W4N OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4W4N FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4w4o\|4w4o]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4w4o\|4w4o]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IGHG1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [http://pdbe.org/4w4n PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [http://www.ebi.ac.uk/pdbsum/4w4n PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4w4n ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [http://pdbe.org/4w4n PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [http://www.ebi.ac.uk/pdbsum/4w4n PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4w4n ProSAT]</span></td></tr>
	</table>		</table>
Line 23:		Line 24:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Caaveiro, J M.M]]		[[Category: Caaveiro, J M.M]]
	[[Category: Kiyoshi, M]]		[[Category: Kiyoshi, M]]

OCA at 01:54, 10 March 2017

2017-03-10T01:54:33Z

←Older revision		Revision as of 01:54, 10 March 2017
Line 1:		Line 1:
		+
	==Crystal structure of human Fc at 1.80 A==		==Crystal structure of human Fc at 1.80 A==
	<StructureSection load='4w4n' size='340' side='right' caption='[[4w4n]], [[Resolution\|resolution]] 1.80Å' scene=''>		<StructureSection load='4w4n' size='340' side='right' caption='[[4w4n]], [[Resolution\|resolution]] 1.80Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4w4o\|4w4o]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4w4o\|4w4o]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [http://www.ebi.ac.uk/pdbsum/4w4n PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [http://pdbe.org/4w4n PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [http://www.ebi.ac.uk/pdbsum/4w4n PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4w4n ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 17:		Line 18:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4w4n" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 06:22, 20 May 2015

2015-05-20T06:22:06Z

←Older revision		Revision as of 06:22, 20 May 2015
Line 9:		Line 9:
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[http://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.		[[http://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[http://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Cell-surface Fcgamma receptors mediate innate and adaptive immune responses. Human Fcgamma receptor I (hFcgammaRI) binds IgGs with high affinity and is the only Fcgamma receptor that can effectively capture monomeric IgGs. However, the molecular basis of hFcgammaRI's interaction with Fc has not been determined, limiting our understanding of this major immune receptor. Here we report the crystal structure of a complex between hFcgammaRI and human Fc, at 1.80 A resolution, revealing an unique hydrophobic pocket at the surface of hFcgammaRI perfectly suited for residue Leu235 of Fc, which explains the high affinity of this complex. Structural, kinetic and thermodynamic data demonstrate that the binding mechanism is governed by a combination of non-covalent interactions, bridging water molecules and the dynamic features of Fc. In addition, the hinge region of hFcgammaRI-bound Fc adopts a straight conformation, potentially orienting the Fab moiety. These findings will stimulate the development of novel therapeutic strategies involving hFcgammaRI.
		+
		+	Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI.,Kiyoshi M, Caaveiro JM, Kawai T, Tashiro S, Ide T, Asaoka Y, Hatayama K, Tsumoto K Nat Commun. 2015 Apr 30;6:6866. doi: 10.1038/ncomms7866. PMID:25925696<ref>PMID:25925696</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 11:36, 30 April 2015

2015-04-30T11:36:13Z

←Older revision		Revision as of 11:36, 30 April 2015
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==Crystal structure of human Fc at 1.80 A==
-		+	<StructureSection load='4w4n' size='340' side='right' caption='[[4w4n]], [[Resolution\|resolution]] 1.80Å' scene=''>
-	~~The entry~~ 4w4n is ~~ON HOLD until Paper Publication~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4w4n]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4W4N OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4W4N FirstGlance]. <br>
-	~~Authors~~: ~~Caaveiro, J~~.M.M., ~~Kiyoshi~~, M., ~~Tsumoto~~, K.	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4w4o\|4w4o]]</td></tr>
-	~~Description~~: ~~Crystal structure of human Fc at 1~~.~~80 A~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4w4n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4w4n OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4w4n RCSB], [http://www.ebi.ac.uk/pdbsum/4w4n PDBsum]</span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	</table>
-	[[~~Category~~: ~~Caaveiro, J~~.M.M]]	+	== Disease ==
-	[[Category: ~~Tsumoto~~, K]]	+	[[http://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[http://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Caaveiro, J M.M]]
	[[Category: Kiyoshi, M]]		[[Category: Kiyoshi, M]]
		+	[[Category: Tsumoto, K]]
		+	[[Category: Human fc asymmetry dynamics immune molecule]]
		+	[[Category: Immune system]]

OCA at 19:05, 24 December 2014

2014-12-24T19:05:41Z

←Older revision		Revision as of 19:05, 24 December 2014
Line 6:		Line 6:

	Description: Crystal structure of human Fc at 1.80 A		Description: Crystal structure of human Fc at 1.80 A
		+	[[Category: Unreleased Structures]]
		+	[[Category: Caaveiro, J.M.M]]
		+	[[Category: Tsumoto, K]]
		+	[[Category: Kiyoshi, M]]

OCA at 09:00, 24 September 2014

2014-09-24T09:00:20Z

←Older revision		Revision as of 09:00, 24 September 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4w4n is ON HOLD	+	The entry 4w4n is ON HOLD until Paper Publication

	Authors: Caaveiro, J.M.M., Kiyoshi, M., Tsumoto, K.		Authors: Caaveiro, J.M.M., Kiyoshi, M., Tsumoto, K.

	Description: Crystal structure of human Fc at 1.80 A		Description: Crystal structure of human Fc at 1.80 A

OCA: Protected "4w4n" [edit=sysop:move=sysop]

2014-08-20T15:16:26Z

Protected "4w4n" [edit=sysop:move=sysop]

←Older revision

Revision as of 15:16, 20 August 2014

OCA: New page: '''Unreleased structure''' The entry 4w4n is ON HOLD Authors: Caaveiro, J.M.M., Kiyoshi, M., Tsumoto, K. Description: Crystal structure of human Fc at 1.80 A

2014-08-20T15:16:24Z

New page: '''Unreleased structure''' The entry 4w4n is ON HOLD Authors: Caaveiro, J.M.M., Kiyoshi, M., Tsumoto, K. Description: Crystal structure of human Fc at 1.80 A

New page

'''Unreleased structure'''

The entry 4w4n is ON HOLD

Authors: Caaveiro, J.M.M., Kiyoshi, M., Tsumoto, K.

Description: Crystal structure of human Fc at 1.80 A